SOUTH SAN FRANCISCO, Calif., Sept. 30, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that the company will present at the Leerink Swann Rare Disease Roundtable on October 2 at the Le Parker Meridien in New York City. KaloBios President and Chief Executive Officer, David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.
When: Wednesday, October 2, 2013, 10:30 AM EDT
Where: Le Parker Meridien, New York City, NY
To access the live and archived audio webcast of this presentation please log on through a link located in the Investors section of the KaloBios Pharmaceuticals website under the Events & Presentations tab: http://leerink.metameetings.com/webcasts/rdroundtable13/directlink?ticker=KBIO.
A replay of the webcast will be available one hour after the conclusion of the live event.
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat severe medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.
Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
Joan E. Kureczka
Tel: (415) 821-2413
Mobile: (415) 690-0210
|SOURCE KaloBios Pharmaceuticals|
Copyright©2012 PR Newswire.
All rights reserved